Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01751022




Registration number
NCT01751022
Ethics application status
Date submitted
3/12/2012
Date registered
17/12/2012
Date last updated
5/12/2016

Titles & IDs
Public title
Attain Performa(TM) Quadripolar Lead Study
Scientific title
Attain Performa(TM) Quadripolar Lead Study
Secondary ID [1] 0 0
Attain Performa(TM)
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Heart Failure 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Device: Attain Performa Pacing Lead (along with a standard CRT-D system)

Experimental: Attain Performa LV Lead (Models 4298, 4398, 4598) - N/A: single arm study, separate analysis for each lead model (total of 3).


Treatment: Devices: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Implant and follow-up of study lead, separate analysis for each lead model
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Lead Complication-free Rate at 6 Months
Timepoint [1] 0 0
Implant to 6 months post-implant
Primary outcome [2] 0 0
LV Pacing Capture Thresholds Per Attain Performa Lead Model
Timepoint [2] 0 0
6 months post-implant
Secondary outcome [1] 0 0
Percentage of Subjects With Presence of PNS in All LV Lead Pacing Polarities
Timepoint [1] 0 0
6 months post-implant
Secondary outcome [2] 0 0
Percentage of Subjects With Successful Implant Per Attain Performa Lead Model
Timepoint [2] 0 0
Implant up to 1-month post implant
Secondary outcome [3] 0 0
Rate of Overall Acceptable Lead Handling Per Attain Performa Lead Model
Timepoint [3] 0 0
Implant up to 1-month post implant
Secondary outcome [4] 0 0
Pacing Capture Thresholds at the Final Programmed Pacing Polarity
Timepoint [4] 0 0
6 months post-implant
Secondary outcome [5] 0 0
Implant Related Times Per Attain Performa Lead Model
Timepoint [5] 0 0
Implant up to 1-month post implant
Secondary outcome [6] 0 0
Pacing Impedance at the Final Programmed Pacing Polarity
Timepoint [6] 0 0
6 month post-implant
Secondary outcome [7] 0 0
Complication Rate for Individual Attain Performa Lead Related Events
Timepoint [7] 0 0
6 month post-Implant

Eligibility
Key inclusion criteria
- Patient is indicated for implant of a CRT-D device and left-heart lead per local
indications (In US only this is based on Class I and II indications for CRT-D implant
per HRS/ACC/AHA guidelines)

- Patient (or legally authorized representative) has signed and dated the study-specific
Consent Form

- Patient is 18 years of age or older, or is of legal age to give informed consent per
local and national law

- Patient is expected to remain available for follow-up visits

- Patient understands the study and agrees to comply with study protocol
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patient has a previous LV lead implanted or previous implant attempt within 30 days of
enrollment or has ongoing AEs from a previous unsuccessful implant attempt

- Patient has contraindications for standard transvenous cardiac pacing (e.g.,
mechanical right heart valve)

- Patient has had a heart transplant (Note: Patients waiting for heart transplants are
allowed in the study)

- Patient is contraindicated for < 1 mg dexamethasone acetate

- Patient is currently enrolled or planning to participate in a potentially confounding
drug or device study during the course of this study. (Note: Co-enrollment in
concurrent studies may be allowed provided that documented pre-approval is obtained
from Medtronic's study manager)

- Patient has a life expectancy less than 180 days

- Patient with exclusion criteria required by local law (e.g. age, pregnancy, breast
feeding, etc.)

- In US, women of childbearing potential must have a negative pregnancy test 7 days
prior to implant to be included

- Patient is unable to tolerate an urgent thoracotomy

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2015
Sample size
Target
Accrual to date
Final
1202
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
- Randwick
Recruitment hospital [2] 0 0
- Chermside
Recruitment hospital [3] 0 0
- Adelaide
Recruitment hospital [4] 0 0
- Heidelberg
Recruitment hospital [5] 0 0
- Perth
Recruitment postcode(s) [1] 0 0
- Randwick
Recruitment postcode(s) [2] 0 0
- Chermside
Recruitment postcode(s) [3] 0 0
- Adelaide
Recruitment postcode(s) [4] 0 0
- Heidelberg
Recruitment postcode(s) [5] 0 0
- Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Iowa
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Mississippi
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nebraska
Country [17] 0 0
United States of America
State/province [17] 0 0
Nevada
Country [18] 0 0
United States of America
State/province [18] 0 0
New Jersey
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
North Dakota
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oklahoma
Country [24] 0 0
United States of America
State/province [24] 0 0
Oregon
Country [25] 0 0
United States of America
State/province [25] 0 0
Pennsylvania
Country [26] 0 0
United States of America
State/province [26] 0 0
South Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
Tennessee
Country [28] 0 0
United States of America
State/province [28] 0 0
Texas
Country [29] 0 0
United States of America
State/province [29] 0 0
Virginia
Country [30] 0 0
United States of America
State/province [30] 0 0
West Virginia
Country [31] 0 0
United States of America
State/province [31] 0 0
Wisconsin
Country [32] 0 0
Austria
State/province [32] 0 0
Graz
Country [33] 0 0
Austria
State/province [33] 0 0
Linz
Country [34] 0 0
Belgium
State/province [34] 0 0
Genk
Country [35] 0 0
Belgium
State/province [35] 0 0
Yvoir
Country [36] 0 0
Canada
State/province [36] 0 0
Calgary
Country [37] 0 0
Canada
State/province [37] 0 0
London
Country [38] 0 0
Canada
State/province [38] 0 0
Montreal
Country [39] 0 0
Canada
State/province [39] 0 0
Newmarket
Country [40] 0 0
Canada
State/province [40] 0 0
Quebec
Country [41] 0 0
Chile
State/province [41] 0 0
Santiago
Country [42] 0 0
Denmark
State/province [42] 0 0
København
Country [43] 0 0
Denmark
State/province [43] 0 0
Århus N
Country [44] 0 0
Finland
State/province [44] 0 0
Helsinki
Country [45] 0 0
France
State/province [45] 0 0
Nantes
Country [46] 0 0
France
State/province [46] 0 0
Rennes Cedex 9
Country [47] 0 0
France
State/province [47] 0 0
Rouen Cedex
Country [48] 0 0
Germany
State/province [48] 0 0
Bad Rothenfelde
Country [49] 0 0
Germany
State/province [49] 0 0
Bernau
Country [50] 0 0
Germany
State/province [50] 0 0
Bielefeld
Country [51] 0 0
Germany
State/province [51] 0 0
Chemnitz
Country [52] 0 0
Germany
State/province [52] 0 0
Heidelberg
Country [53] 0 0
Germany
State/province [53] 0 0
Trier
Country [54] 0 0
Greece
State/province [54] 0 0
Athens
Country [55] 0 0
Hungary
State/province [55] 0 0
Budapest
Country [56] 0 0
India
State/province [56] 0 0
Haryana
Country [57] 0 0
India
State/province [57] 0 0
Dehli
Country [58] 0 0
Israel
State/province [58] 0 0
Ashkelon
Country [59] 0 0
Italy
State/province [59] 0 0
Bologna
Country [60] 0 0
Italy
State/province [60] 0 0
Cefalù
Country [61] 0 0
Italy
State/province [61] 0 0
Rovigo
Country [62] 0 0
Malaysia
State/province [62] 0 0
Kuala Lumpur
Country [63] 0 0
Netherlands
State/province [63] 0 0
Eindhoven
Country [64] 0 0
Netherlands
State/province [64] 0 0
Maastricht
Country [65] 0 0
Netherlands
State/province [65] 0 0
Nieuwegein
Country [66] 0 0
Norway
State/province [66] 0 0
Bergen
Country [67] 0 0
Romania
State/province [67] 0 0
Bucuresti
Country [68] 0 0
Saudi Arabia
State/province [68] 0 0
Riyadh
Country [69] 0 0
Serbia
State/province [69] 0 0
Beograd
Country [70] 0 0
Serbia
State/province [70] 0 0
Niš
Country [71] 0 0
Serbia
State/province [71] 0 0
Sremska Kamenica
Country [72] 0 0
Slovakia
State/province [72] 0 0
Bratislava 37
Country [73] 0 0
Slovakia
State/province [73] 0 0
Kosice
Country [74] 0 0
Slovenia
State/province [74] 0 0
Ljublijana
Country [75] 0 0
South Africa
State/province [75] 0 0
Cape Town
Country [76] 0 0
Spain
State/province [76] 0 0
Madrid
Country [77] 0 0
Switzerland
State/province [77] 0 0
Lausanne
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Bournemouth
Country [79] 0 0
United Kingdom
State/province [79] 0 0
London
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Medtronic Cardiac Rhythm and Heart Failure
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to evaluate the safety and efficacy of the Medtronic Attain
Performa Quadripolar Leads (Model 4298, 4398, and 4598) during and post the implant
procedure. This study will also assess the interactions of the Attain Performa leads with the
entire Medtronic CRT-D system.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01751022
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01751022